Chinese specialty pharma that in-licenses drugs from global partners and markets them to Chinese hospitals.
Chinese specialty pharma that in-licenses drugs from global partners and markets them to Chinese hospitals.
Buys the rights to sell drugs in China from foreign and domestic developers, then markets them through its own sales force to hospitals and through distributors, keeping the margin between sales and what it pays for the rights. Growth comes from adding drugs, so the licensing pipeline matters as much as sales.
In one line: A Chinese drug-licensing/marketing specialist.
Moat: narrow (distribution, regulatory licence). Established hospital sales force and regulatory relationships ease new in-licensed launches.
Headquarters: Shenzhen, China · Founded: 2000 · Employees: 6,415
Size China Medical System (0867.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $2.95B, the 336th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$9.59 on 18 Nov 2026.
Performance Over six months the shares fell 15.2%, against -6.6% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 6th lowest of 21 in its peer set.
Growth Revenue grew 14.8% over the last twelve months (peer median +9.4%); the operating margin is 20.0% (peer median 11.3%).
Valuation It trades at 9.8× forward earnings against a peer median of 28.6× (cheapest of 17).
Price implies For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is -2 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 0.6 points above its cost of capital (9.9% WACC).
Next results Next results expected around 16 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$9.74B | HK$8.91B | HK$8.10B | HK$8.85B | HK$10.6B |
| Revenue growth | — | +10% | -9% | -17% | — |
| Gross profit | HK$6.93B | HK$6.37B | HK$5.88B | HK$6.75B | HK$8.18B |
| EBITDA | HK$2.26B | HK$2.00B | HK$2.07B | HK$3.20B | HK$4.40B |
| Net income | HK$1.72B | HK$1.61B | HK$1.76B | HK$2.65B | HK$3.79B |
| Free cash flow | HK$1.29B | HK$1.14B | HK$1.64B | HK$3.06B | HK$4.22B |
| Capital expenditure | HK$886M | HK$558M | HK$494M | HK$351M | HK$610M |
| Total debt | n/a | HK$769M | HK$916M | HK$1.43B | HK$2.04B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| China Medical System 0867.HK | $2.95B | -15% | +15% | 20% | 9.8× | 1.1% |
| Livzon Pharmaceutical 1513.HK | $3.73B | -9% | -10% | 19% | 11.3× | -7.0% |
| Simcere Pharmaceutical 2096.HK | $3.42B | -5% | +27% | 18% | 13.5× | -3.4% |
| Shanghai Fosun Pharmaceutical (Group) 2196.HK | $7.74B | -15% | +10% | 6% | 9.0× | 19.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 0867.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -7.7% | +0.3% | 8th lowest of 21 |
| 6-month return | -15.2% | -6.6% | 6th lowest of 21 |
| Distance from 52-week high | -38.2% | -29.6% | 8th lowest of 21 |
| Revenue growth (TTM) | +14.8% | +9.4% | 10th highest of 20 |
| Operating margin | 20.0% | 11.3% | 6th highest of 20 |
| Forward P/E | 9.8× | 28.6× | cheapest of 17 |
| Growth the price implies (Req g, 7 yrs) | 1.1% | 9.2% | 6th least demanding of 14 |
| Growth delivered (Del g) | +2.7% | +10.6% | 3rd lowest of 14 |
| Hurdle (Req g minus delivered) | -1.6 pp | -10.2 pp | 6th most demanding of 14 |
| ROIC minus cost of capital | +0.6 pp | +3.0 pp | 7th lowest of 17 |
| EV / EBITDA | 7.8× | 27.6× | cheapest of 8 |
| Net debt / EBITDA | -2.5× | -0.8× | 3rd least indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| China Medical System 0867.HK | Hong Kong | $2.95B | -15% | +15% | 20% | 9.8× | 1.1% | +2.7% |
| Neuland Laboratories NEULANDLAB.NS | India | $2.95B | +28% | +50% | 26% | 63.4× | n/a | n/a |
| Chengdu Kanghong Pharmaceutical 002773.SZ | China | $2.99B | -1% | -11% | 24% | 20.1× | -3.3% | +7.0% |
| Vericel VCEL | United States | $2.99B | +66% | +25% | 8% | 68.3× | 46.5% | +17.3% |
| Joincare Pharmaceutical Group Industry 600380.SS | China | $2.85B | 0% | -12% | 18% | 15.5× | -13.1% | +2.4% |
| Shanghai Henlius Biotech 2696.HK | Hong Kong | $3.05B | -39% | +33% | 12% | 21.3× | 14.1% | +61.4% |
| ACADIA Pharmaceuticals ACAD | United States | $3.08B | -15% | +15% | 10% | 17.8× | 9.2% | +19.4% |
| Legend Biotech Corp. Sponsored ADR LEGN | United States | $3.12B | -42% | +50% | 3% | 34.2× | n/a | n/a |
| Suzhou Zelgen Biopharmaceuticals 688266.SS | China | $3.13B | -25% | +136% | 29% | 36.1× | 17.7% | +98.4% |
| Tasly Pharmaceutical 600535.SS | China | $3.19B | -2% | -4% | 19% | 16.7× | -7.5% | -9.6% |
| Betta Pharmaceuticals 300558.SZ | China | $2.70B | -15% | +16% | 11% | 38.0× | 23.2% | +14.0% |
| Hybio Pharmaceutical 300199.SZ | China | $2.68B | -8% | +70% | 31% | 44.7× | 37.4% | +6.1% |
| China National Medicines 600511.SS | China | $3.26B | +3% | +3% | 4% | 10.5× | -10.0% | +5.4% |
| BioArctic BIOA-B.ST | Sweden | $2.66B | -9% | -46% | 22% | 52.9× | 25.5% | +100.1% |
| Kangmei Pharmaceutical 600518.SS | China | $2.61B | -21% | -6% | -7% | n/a | n/a | n/a |
| Viking Therapeutics VKTX | United States | $3.34B | -9% | n/a | n/a | n/a | n/a | n/a |
| Apeloa Pharmaceutical 000739.SZ | China | $3.37B | +17% | -16% | 10% | 22.9× | 4.7% | +4.5% |
| IDEAYA Biosciences IDYA | United States | $2.56B | -11% | -83% | -1,267% | n/a | n/a | n/a |
| Piramal Pharma PPLPHARMA.NS | India | $3.40B | +38% | +9% | 3% | 150.8× | n/a | n/a |
| Simcere Pharmaceutical 2096.HK | Hong Kong | $3.42B | -5% | +27% | 18% | 13.5× | -3.4% | +10.6% |
| Viridian Therapeutics VRDN | United States | $3.42B | +71% | -63% | -1,781% | n/a | n/a | n/a |